MannKind (NASDAQ:MNKD), a biopharmaceutical firm known for its inhaled insulin and pulmonary therapeutics, released its second quarter 2025 earnings on August 6, 2025. The most si ...

MannKind Corporation (Nasdaq: MNKD), a company focused on the development and commercialization of inhaled therapeutic products and delivery devices for patients with endocrine and orphan lung ...

Westlake Village-based MannKind Corporation is receiving some extra help to advance some of its short and long-term growth strategies. Announced Aug. 6, MannKind, a biotech company focused on inhaled ...